Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
38.00 x 1 51.00 x 1
Post-market by (Cboe BZX)
40.67 -0.65 (-1.57%) 02/14/25 [NASDAQ]
38.00 x 1 51.00 x 1
Post-market 40.67 unch (unch) 16:52 ET
Quote Overview for Fri, Feb 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
40.13
Day High
42.23
Open 41.50
Previous Close 41.32 41.32
Volume 1,461,500 1,461,500
Avg Vol 1,283,520 1,283,520
Stochastic %K 26.15% 26.15%
Weighted Alpha +19.98 +19.98
5-Day Change -1.52 (-3.60%) -1.52 (-3.60%)
52-Week Range 28.43 - 62.40 28.43 - 62.40
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,841,466
  • Shares Outstanding, K 168,219
  • Annual Sales, $ 11,580 K
  • Annual Income, $ -436,370 K
  • EBIT $ -653 M
  • EBITDA $ -666 M
  • 60-Month Beta 1.45
  • Price/Sales 8,745.43
  • Price/Cash Flow N/A
  • Price/Book 4.41

Options Overview Details

View History
  • Implied Volatility 49.82% ( +0.36%)
  • Historical Volatility 37.02%
  • IV Percentile 21%
  • IV Rank 8.37%
  • IV High 147.63% on 07/11/24
  • IV Low 40.89% on 01/14/25
  • Put/Call Vol Ratio 0.79
  • Today's Volume 68
  • Volume Avg (30-Day) 191
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 18,836
  • Open Int (30-Day) 20,287

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.99
  • Number of Estimates 10
  • High Estimate -0.92
  • Low Estimate -1.15
  • Prior Year -1.14
  • Growth Rate Est. (year over year) +13.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.36 +3.33%
on 01/21/25
Period Open: 39.83
44.68 -8.97%
on 02/05/25
+0.84 (+2.11%)
since 01/14/25
3-Month
39.36 +3.33%
on 01/21/25
Period Open: 57.37
59.72 -31.90%
on 11/26/24
-16.70 (-29.11%)
since 11/14/24
52-Week
28.43 +43.05%
on 02/21/24
Period Open: 29.72
62.40 -34.82%
on 11/11/24
+10.95 (+36.84%)
since 02/14/24

Most Recent Stories

More News
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

RVMD : 40.67 (-1.57%)
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

RVMD : 40.67 (-1.57%)
Revolution Medicines Closes $862.5 Million Underwritten Public Offering of Common Stock

Revolution Medicines closed a public offering of 16.6 million shares, raising $862.5 million for RAS-addicted cancer therapies.Quiver AI SummaryRevolution Medicines, Inc. has successfully completed its...

RVMD : 40.67 (-1.57%)
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

RVMD : 40.67 (-1.57%)
Revolution Medicines Prices Public Offering of Common Stock and Pre-Funded Warrants, Aiming for $750 Million in Proceeds

Revolution Medicines announced a public offering of 14.1 million shares priced at $46 each, aiming for $750 million proceeds.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...

RVMD : 40.67 (-1.57%)
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

RVMD : 40.67 (-1.57%)
Revolution Medicines, Inc. Provides Promising Clinical Updates on RMC-6236 for RAS-Addicted Cancers

Revolution Medicines provides updates on RMC-6236 and RMC-6291 in clinical trials for RAS-addicted cancers.Quiver AI SummaryRevolution Medicines, Inc. provided a clinical update on its RAS(ON) inhibitor...

RVMD : 40.67 (-1.57%)
Revolution Medicines Announces Commencement of Public Offering of Common Stock

RVMD : 40.67 (-1.57%)
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

RVMD : 40.67 (-1.57%)
Revolution Medicines to Host Investor Webcast on RAS(ON) Inhibitor Clinical Updates

Revolution Medicines will host an investor webcast on December 2, 2024, to discuss updates on its RAS(ON) inhibitor portfolio.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...

RVMD : 40.67 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 43.99
2nd Resistance Point 43.11
1st Resistance Point 41.89
Last Price 40.67
1st Support Level 39.79
2nd Support Level 38.91
3rd Support Level 37.69

See More

52-Week High 62.40
Fibonacci 61.8% 49.42
Fibonacci 50% 45.42
Fibonacci 38.2% 41.41
Last Price 40.67
52-Week Low 28.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion